BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

127 related articles for article (PubMed ID: 18600412)

  • 1. Does cisplatin chemotherapy decrease the MDP uptake of normal bone? An experimental study.
    Ozdogan O; Ertay T; Arslan G; Sisman AR; Capa Kaya G; Yilmaz O; Coker C; Gure A; Durak H
    Ann Nucl Med; 2008 Jun; 22(5):357-62. PubMed ID: 18600412
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Is (99m)Tc-labelled pamidronate a better agent than (99m)Tc-medronate for bone imaging?
    Kumar V; Kumar D; Howman-Giles RB; Little DG
    Nucl Med Commun; 2007 Feb; 28(2):101-7. PubMed ID: 17198350
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Validation of a blood-sampling method for the measurement of 99mTc-methylene diphosphonate skeletal plasma clearance.
    Moore AE; Blake GM; Fogelman I
    J Nucl Med; 2006 Apr; 47(4):581-6. PubMed ID: 16595490
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The effect of MRI contrast agents on hepatic and splenic uptake in the rabbit during (99m) Tc-MDP bone scintigraphy.
    Qiu L; Tang Y; Chen Y; Huang Z; Zhu Y; Zhang L; Cai L; Wan Q; Feng Y
    Contrast Media Mol Imaging; 2015; 10(6):438-45. PubMed ID: 26036779
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Studies on 177Lu-labeled methylene diphosphonate as potential bone-seeking radiopharmaceutical for bone pain palliation.
    Abbasi IA
    Nucl Med Biol; 2011 Apr; 38(3):417-25. PubMed ID: 21492790
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A report on the incidence of intestinal 99mTc-methylene diphosphonate uptake of bone scans and a review of the literature.
    Ergün EL; Kiratli PO; Günay EC; Erbaş B
    Nucl Med Commun; 2006 Nov; 27(11):877-85. PubMed ID: 17021428
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Quantitative measurements of bone remodeling using 99mTc-methylene diphosphonate bone scans and blood sampling.
    Moore AE; Blake GM; Fogelman I
    J Nucl Med; 2008 Mar; 49(3):375-82. PubMed ID: 18287266
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Analysis of contributing factors with high renal uptake of 99mTc-MDP after anti-cancer chemotherapy including cisplatin].
    Sato T; Yoshioka S; Ogata Y; Abe Y; Takahashi J; Yamada K; Ono S; Fukuda H
    Kaku Igaku; 1996 Nov; 33(11):1221-6. PubMed ID: 8986061
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Mechanism of accumulation of 99mTc-MDP to bone: correlation of in vivo data with in vitro data.
    Okamoto YM
    Radiat Med; 1997; 15(4):209-15. PubMed ID: 9311035
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A study to determine the dependence of 99mTc-MDP protein binding on plasma clearance and serum albumin concentration.
    Moore AE; Blake GM; Fogelman I
    Nucl Med Commun; 2007 Mar; 28(3):187-92. PubMed ID: 17264777
    [TBL] [Abstract][Full Text] [Related]  

  • 11.
    Mandiwana V; Kalombo L; Grobler A; Zeevaart JR
    Appl Radiat Isot; 2018 Nov; 141():51-56. PubMed ID: 30170270
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Bone uptake studies in rabbits before and after high-dose treatment with 153Sm-EDTMP or 186Re-HEDP.
    Brenner W; Kampen WU; Brümmer C; von Forstner C; Zuhayra M; Czech N; Muhle C; Henze E
    J Nucl Med; 2003 Feb; 44(2):247-51. PubMed ID: 12571217
    [TBL] [Abstract][Full Text] [Related]  

  • 13. (99m)Tc-interleukin-8 for imaging acute osteomyelitis.
    Gratz S; Rennen HJ; Boerman OC; Oyen WJ; Burma P; Corstens FH
    J Nucl Med; 2001 Aug; 42(8):1257-64. PubMed ID: 11483689
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Quantitative studies of bone using (99m)Tc-methylene diphosphonate skeletal plasma clearance.
    Blake GM; Moore AE; Fogelman I
    Semin Nucl Med; 2009 Nov; 39(6):369-79. PubMed ID: 19801217
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A comparison of bone imaging with Tc-99m DPD and Tc-99m MDP: concise communication.
    Buell U; Kleinhans E; Zorn-Bopp E; Reuschel W; Muenzing W; Moser EA; Seiderer M
    J Nucl Med; 1982 Mar; 23(3):214-7. PubMed ID: 6460854
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Influence of low grade exercise on skeletal scintigraphy using Tc-99m methylene diphosphonate.
    Amin A; El-Kareem MA; Yahia AB
    Nucl Med Rev Cent East Eur; 2015; 18(2):61-4. PubMed ID: 26315864
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Computer analysis of Tc-99m DPD and Tc-99m MDP kinetics in humans: concise communication.
    Mele M; Conte E; Fratello A; Pasculli D; Pieralice M; D'Addabbo A
    J Nucl Med; 1983 Apr; 24(4):334-8. PubMed ID: 6834136
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Prediction of tumor absorbed dose by Tc-99m-MDP scintigraphy prior to treatment with Sr-89.
    Manetou A; Limourls GS
    Anticancer Res; 1997; 17(3B):1845-7. PubMed ID: 9179243
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Dosimetric considerations of
    Brown JL; Sexton-Stallone B; Li Y; Frey EC; Treves ST; Fahey FH; Plyku D; Cao X; Choi C; Kim CH; Sgouros G; Aris JP; Bolch WE
    Phys Med Biol; 2020 Dec; 65(23):235025. PubMed ID: 33263312
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Atypical Paget's disease with quantitative assessment of tracer kinetics.
    Gnanasegaran G; Moore AE; Blake GM; Vijayanathan S; Clarke SE; Fogelman I
    Clin Nucl Med; 2007 Oct; 32(10):765-9. PubMed ID: 17885354
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.